1文献来源研究一:Janssen QP,Buettner S,Suker M,et al.Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer:A systematic review and patient level meta analysis[J].J Natl Cancer Inst,2019,111(8)...1文献来源研究一:Janssen QP,Buettner S,Suker M,et al.Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer:A systematic review and patient level meta analysis[J].J Natl Cancer Inst,2019,111(8):782-794.研究二:Katz MH,Shi Q,Ahmad SA,et al.Preoperative modified FOLFIRINOX treatment followed by Capecitabine based chemoradiation for borderline resectable pancreatic cancer:Alliance for clinical trials in oncology trial A021101[J].JAMA Surg,2016,151(8):e161137.2证据水平1b。展开更多
1文献来源Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or Gemcitabin as adjuvant therapy for pancreatic cancer[J].N Eng J Med,2018,379(25):2395-2406.2证据水平1b。3背景胰腺癌单纯手术治疗的5年生存率较低,即使接受了吉西他...1文献来源Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or Gemcitabin as adjuvant therapy for pancreatic cancer[J].N Eng J Med,2018,379(25):2395-2406.2证据水平1b。3背景胰腺癌单纯手术治疗的5年生存率较低,即使接受了吉西他滨或者氟尿嘧啶辅助治疗,仍有大约70%的患者会在2年内出现转移复发[1 2]。因此,探索新的胰腺癌辅助治疗策略具有十分重要的临床意义。作为转移性胰腺癌的一线治疗,与吉西他滨单药化疗相比,FOLFIRINOX方案(持续泵注5 氟尿嘧啶+亚叶酸钙+伊立替康+奥沙利铂)明显延长了患者的总生存期(overall survival,OS)[3]。但FOLFIRINOX方案作为胰腺癌切除术后辅助治疗的价值尚不明确。展开更多
文摘1文献来源研究一:Janssen QP,Buettner S,Suker M,et al.Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer:A systematic review and patient level meta analysis[J].J Natl Cancer Inst,2019,111(8):782-794.研究二:Katz MH,Shi Q,Ahmad SA,et al.Preoperative modified FOLFIRINOX treatment followed by Capecitabine based chemoradiation for borderline resectable pancreatic cancer:Alliance for clinical trials in oncology trial A021101[J].JAMA Surg,2016,151(8):e161137.2证据水平1b。
文摘1文献来源Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or Gemcitabin as adjuvant therapy for pancreatic cancer[J].N Eng J Med,2018,379(25):2395-2406.2证据水平1b。3背景胰腺癌单纯手术治疗的5年生存率较低,即使接受了吉西他滨或者氟尿嘧啶辅助治疗,仍有大约70%的患者会在2年内出现转移复发[1 2]。因此,探索新的胰腺癌辅助治疗策略具有十分重要的临床意义。作为转移性胰腺癌的一线治疗,与吉西他滨单药化疗相比,FOLFIRINOX方案(持续泵注5 氟尿嘧啶+亚叶酸钙+伊立替康+奥沙利铂)明显延长了患者的总生存期(overall survival,OS)[3]。但FOLFIRINOX方案作为胰腺癌切除术后辅助治疗的价值尚不明确。
